iner K. A., Hawiger A., Gelfand J. A. The effect of cobra venom factor on alternative pathway hemolytic activity in mice, Immunol. Commun., 9, 277—281 (1980).

90. Lachman P. J., Hobart M. /., Aston W. P. Complement technology. In: Experimental Immunology, ed. by D. M. Weir, pp. 5A.1—5A.23. Blackwell Scientific Publications, Oxford, England, 1973. д. Дж. Браун, К. А. Джойнер, М. М. Фрэнк

91. Hong К., Kinoshita Т., Kitajima Н., Inoue К. Inhibitory effect of К-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivatory system, J. Immunol., 127, 104-108 (1981).

92. Hong K., Kinoshita Т., Inoue K. Simple methods for preparing EAC/4b2a3b and EAC4b3b with human or guinea pig complement components using an anticomplementary agent, K-76 monocarboxylic acid, J. Immunol., 127, 109—114 (1981).

93. Doha M. R., Austen K. F., Fercn D. T. Heterogeneity of polypeptide chain composition and antigenic reactivity of C3 nephritic factor, J. Immunol., 120, 1389—1394 (1978).

94. Davis A. E., Ziegler J. В., Gelfand E. W., Rosen F. S., AlperC. A. Heterogeneity of nephritic factor and its identification as an immunoglobulin, Proc. Natl. Acad. Sci. USA.T4, 3980—3983 (1977).

95. Burge J. J., Fearon D. Т., Austen K. F. Inhibition of the alternative pathway of complement by gold sodium thiomalate in vitro, J. Immunol., 120, 1625—1630 (1978).

96. Kancko I., Fearon D. Т., Austen K. F. Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin, J. Immunol., 124, 1194—1198 (1980).

97. MayJ. E., Frank M. M. A new complement mediated cytolytic mechanism: The Cl-bypass activation pathway, Proc. Natl. Acad. Sci. USA, 70, 649—652 (1973).

98. Nelson R.A., Jr. Complement and body defenses, Transfusion, 3, 250—259 (1963).

99. Inoue K., Nelson R. A., Jr. The isolation and characterization of a new component of hemolytic complement, С'Зе, J. Immunol., 95, 355—367 (1965).

100. Linscott W. D., Nishioka K. Components of guinea pig complement. II. Separation of serum fractions essential for immune hemolysis, J. Exp. Med., 118, 795—815 (1963).

101. Nilsson U. R., Muller-Eberhard H. J. Isolation of beta IF globulin from human serum and its characterization as the fifth component of complement, J. Exp. Med., 122, 277—298 (1965).

102. Nelson R. A., Jr., Jensen J., Gigli I., Tamura N. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea pig serum, Immunochemistry, 3, 111—135 (1966).

103. Mayer M. M. Mechanism of cytolysis by complement, Proc. Natl. Acad. Sci. USA, 69, 2954_2958 (1972).

104. Mayer M. M., MichaelsD. W.,RammL. E., Whitlow M. В., WilloughbyJ. В., ShinM.L. Membrane damage by complement, Crit. Rev. Immunol., 2, 133—166 (1981).

105. Boyle M. D. P., Borsos T. The terminal stages of immune hemolysis — a brief review, Mol. Immunol., 17, 425—432 (1980).

106. Green H., Barrow P., Goldberg B. Effect of antibody and complement on permeability control in ascites tumor cells and erythrocytes, J. Exp. Med., 110, 699—713 (1959).

107. Giavedone E. В., Chow Y. M., Dalmasso A. P. The functional size of the primary complement lesion in resealed erythrocyte membrane ghosts, J. Immunol., 122, 240—245 (1979).

108. Ramm L. E., Mayer M. M. Life-span and size of the trans-membrane channel formed by large doses of complement, J. Immunol., 124, 2281—2287 (1980).

109. Simone С. В., Henkart P. Inhibition of marker influx into complement-treated resealed erythrocyte ghosts by anti-C5, J. Immunol., 128, 1168—1175 (1982).

110. Sims P. J., Lauf P. K. Analysis of solute diffusion across the C5b-9 membrane lesion of complement: Evidence that individual C5b-9 complexes do not function as discrete, uniform pores, J. Immunol., 125, 2617—2625 (1980).

111. Shin H. S., Snyderman R., Friedman E., Mellors A., Mayer M. M. Chemotactic and ana-phylatoxic fragment cleaved from the fifth component of guinea pig complement, Science, 162, 361—363 (1968).

112. Snyderman R., Shin H. S., Phillips J. K., Gewurz H., Mergenhagen S. E. A neutrophil chemotactic factor derived from C'5 upon interaction of guinea pig serum with endotoxin, J. Immunol., 103, 413—422 (1969).

113. Doha M. R., Fearon D. Т., Austen K. F. C3 requirements for formation of alternative pathway C5 convertase, J. Immunol., 117, 630—634 (1976).

114. Medicus R. G., Gbtze O., Muller-Eberhard H. J. Alternative pathway of complement: Recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway, J. Exp. Med., 144, 1076—1093 (1976).

115. Golstein I. M., Perez H. D. Biologically active peptides derived from the fifth component of complement, Prog. Hemost. Thromb., 5, 41—79 (1980).

116. Cooper N. R., Muller-Eberhard H. J. The reaction mechanism of human C5 in immune hemolysis, J. Exp. Med., 132, 775—793 (1970).

117. Lachmann P. J., Thompson R. A. Reactive lysis: The complement-mediated lysis of un-sensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9, J. Exp. Med., 131, 643—657 (1970).

24. Комплемент 118. Thompson R. A., Lachmann P. J. Reactive lysis: The complement-mediated lysis of un-sensitized cells. I. The characterization of the indicator factor and its identification as C7, J. Exp. Med., 131, 629—641 (1970).

119. Podack E. R., Kolb W. P., Muller-Eberhard ff. J. The C5b-6 complex: Formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum, J. Immunol., 120, 1841—1848 (1978).

120. Yamamota A'., Gewurz ff. The complex of C5b and C6: Isolation, characterization, and identification of a modified form of C5b consisting of three polypeptide chains, J. Immunol., 120, 2008—2015 (1978).

121. BakerP. J., Lint T. F., McLeodB. C, Behrends C. L., Gewurz ff. Studies on the inhibition of C56-induced lysis (reactive lysis) VI. Modulation of C56-induced lysis by polyanions and polycations, J. Immunol., 114, 554—558 (1975).

122. Nembrow G. R., Yamamoto K., Lint T. F. Restriction of complement-mediated membrane damage by the eighth component of complement. A dual role for C8 in the complement attach sequence, J. Immunol., 123, 1245—1251 (1979).

123. Kolb W. P., Muller-Eberhard ff. J. The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution, J. Exp. Med., 138, 438—451 (1973).

124. Kolb W. P., Muller-Eberhard ff. J. The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex, J. Exp. Med., 141, 724—735 (1975).

125. Podack E. R., Muller-Eberhard ff. J. Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components, J. Immunol., 121, 1025—1030 (1978).

126. Bhakdi S., Bjerrum O. J., Bother U., Kniijermann II., Wallach D. F. H. Immunochemical analyses of membrane-bound complement detection of the terminal complement complex and its similarity to ((intrinsic* erythrocyte membrane proteins, Biochim. Biophys. Acta, 406, 21-35 (1975).

127. BieseckerG., Podack E. R., ffalverson C. A., Muller-Eberhard ff. J. C5b-9 Dimer: Isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions, J. Exp. Med., 149, 448—458 (1979).

128. Ware C. F., Wetsel R. A., Kolb W. P. Physicochemical characterization of fluid phase (SC5b-9) and membrane derived (MC5b-9) attack complexes of human complement purified by immunoadsorbent affinity chromatography or selective detergent extraction, Mol. Immunol., 18, 521—531 (1981).

129. Ware C. F., Kolb W. P. Assembly of the functional membrane attack complex of human complement: Formation of disulfide-linked C9 dimers, Proc. Natl. Acad. Sci. USA, 78, 6426—6430 (1981).

130. Humphrey J. ff., Dourmashkin R. R. The lesions in cell membranes caused by complement, Adv. Immunol., 11, 75—115 (1969).

131. Tranum-Jensen J., Bhakdi S., Bhakdi-Lehnen В., Bjerrum O. J., Speth V. Complement lysis: The ultrastructure and orientation of the C5b-9 on target sheep erythrocyte membranes, Scand. J. Immunol., 7, 45—56 (1978).

132. Bhakdi S., Tranum-J ensen J. Molecular nature of the complement lesion, Proc. Natl. Acad. Sci. USA, 75, 5655—5659 (1979).

133. Rauterberg E. W., Ungemach В., Gebest ff. Quantitative measurement of C9 sites and their assotiation to the ring-like «lesions» on complement-lysed membranes: A morphometric immunoferritin study, J. Immunol., 122, 355—365 (1979).

134. Bhakdi S., Tranum-J ensen J., Klump O. The terminal membrane C5b-9 complex of human complement. Evidence for the existence of multiple protease-resistant polypeptides that form the trans-membrane complement channel, J. Immunol., 124, 2451—2457 (1980).

135. Podack E. R., Tschopp J. Polymerization of the ninth component of complement. Formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement, Proc. Natl. Acad. Sci. USA, 79, 574—578 (1982).

136. Podack E. R., Tschopp J., Muller-Eberhard ff. J. Molecular organization of C9 within the membrane attack complex of complement, J. Exp. Med., 156, 268—282 (1982).

137. Kolb W. P., Muller-Eberhard ff. J. Neoantigens of the membrane attack complex of human complement, Proc. Natl. Acad. Sci. USA, 72, 1687—1689 (1975).

138. Sundsmo J. S., Curd J. G., Kolb W. P., Muller-Eberhard II. J. Leukocyte complement: Assembly of the membrane attack complex by human peripheral blood leukocytes in the presence and absence of serum, J. Immunol., 120, 855—860 (1978).

139. Alper C. A., Rosen F. S. Genetics of the complement system. In: Advances in Human Genetics Vol. 7, ed. by II. Harris and K. Hirschhorn, pp. 141—188, Plenum Press, London, 1976. Э. Дж. Браун, К. А. Джойнер, М. М. Фрэнк

140. Whaley К. Biosynthesis of the complement components and the regulatory